New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 10, 2014
08:10 EDTRCPTReceptos risk/reward attractive following data, says Leerink
Leerink believes the Phase II data for RPC-1063 suggests the drug is meaningfully differentiated from other therapies in development at least for patients with relapsing forms of multiple sclerosis. The firm reiterates an Outperform rating on shares of Receptos with a $75 price target and views the risk/reward as attractive.
News For RCPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 17, 2015
10:00 EDTRCPTOn The Fly: Analyst Initiation Summary
Subscribe for More Information
05:55 EDTRCPTReceptos initiated with a Buy at UBS
Subscribe for More Information
April 16, 2015
09:30 EDTRCPTReceptos announcement a positive surprise, says Leerink
Subscribe for More Information
08:08 EDTRCPTReceptos reports positive results for maintenance period of ozanimod trial
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use